MAP2K7 and cancer: Dabrafenib in combination with MEK inhibitors has already yielded impressive results, but dabrafenib also blocks necroptosis by interference with RIP3 kinase activity41, suggesting that the selection of kinase inhibitors to target cancer cell death must consider how cell death machinery is involved and the RIP3 expression pattern in cancer cells.